KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Non-Current Debt (2016 - 2025)

AbbVie (ABBV) has disclosed Non-Current Debt for 14 consecutive years, with $58.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 2.32% to $58.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $58.9 billion, a 2.32% decrease, with the full-year FY2025 number at $58.9 billion, down 2.32% from a year prior.
  • Non-Current Debt was $58.9 billion for Q4 2025 at AbbVie, down from $63.0 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $74.2 billion in Q2 2021 to a low of $52.2 billion in Q4 2023.
  • A 5-year average of $62.2 billion and a median of $60.7 billion in 2022 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: grew 17.22% in 2021, then fell 18.43% in 2022.
  • AbbVie's Non-Current Debt stood at $64.2 billion in 2021, then fell by 7.87% to $59.1 billion in 2022, then fell by 11.74% to $52.2 billion in 2023, then increased by 15.61% to $60.3 billion in 2024, then dropped by 2.32% to $58.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Non-Current Debt are $58.9 billion (Q4 2025), $63.0 billion (Q3 2025), and $63.0 billion (Q2 2025).